The HOLD Study
Research type
Research Study
Full title
Hearing From YOU: Research Opportunities for People with Learning Disabilities: The HOLD Study
IRAS ID
360590
Contact name
Hermione Price
Contact email
Sponsor organisation
Hampshire and Isle of Wight NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 31 days
Research summary
Summary of Research: People with learning disabilities are less likely to receive health care, see their GP and more likely to die prematurely compared to those without learning disabilities or the general population. They are typically all but excluded from clinical research because of exclusion criteria such as those excluding people who cannot read or write English or may have difficulty complying with the requirements of the protocol in full. In addition, funding formulas leave no room to make any adjustments for people with learning disabilities such as allowing more time for a blood test or informed consent to be taken or allowing additional visits to complete the requirements of the protocol. This means that some of the people with the greatest needs and therefore, the potential for greater benefit, are effectively being excluded from participating in clinical research.
Whilst literacy and social capabilities range a great deal amongst people with learning disabilities our aim is to better understand how we can include people with learning disabilities in all kinds of clinical research and what adjustments might be needed to allow this to happen.
We wish to undertake a series of scoping workshops some with people with learning disabilities, their carers and families and some with professionals across health and social care involved in providing care for people with learning disabilities to explore their thoughts about clinical research and the barriers and facilitators to participation. Our aim is to hold 3 scoping workshops for people with learning disabilities and their carers and families and two for professionals.Summary of Results: There are approximately 1.5 million adults living in the UK with a learning disability. LD can be defined as a reduced ability to fully comprehend complex or new information, to function independently or to learn new skills throughout life. The International Classification of Diseases-11 (ICD-11) classifies LD as disorders of intellectual development. Adults with LD are more likely to have co-existing physical and mental health co-morbidities and to develop these at a younger age and in greater number, than adults without a LD. Common co-morbidities include obesity and type 2 diabetes, which are potentially preventable. However, there is a distinct lack of inclusion of adults with LD in clinical trials of new medicines, technologies and other interventions, with only 2% of clinical studies explicitly allowing participation. Clarity is lacking regarding the relative effectiveness of medicines, technologies and interventions in LD and non-LD populations, or if alternate strategies are required.
Increasing inclusion of the LD population in clinical research and thus increasing representation could help identify healthcare benefits for this population. Previous research shows that with minor modifications many studies would allow those with LD to participate, therefore there is a demand for studies to explore ways in which inclusivity could be increased. Our research aimed to explore mechanisms of overcoming existing barriers that prevent adults with LD from taking part in clinical research and to improve opportunities for future participation.
Methods
This qualitative study was sponsored by Hampshire and Isle of Wight (HIOW) Healthcare NHS Foundation Trust and funded by the NIHR South Central RRDN Strategic Funding Call 2025/26. The study was approved by the South Central - Hampshire A Research Ethics Committee (reference 25/SC/0366) on 5th December 2025. Recruitment of participants began on 10th of December 2025 and data collection occurred between 20th February and 24th April 2026. This study was designed in consultation with family members of those with LD and voluntary, community and social enterprise (VCSE) organisations.Eligible participants were adults 18 years of age or older with capacity and an LD as per the ICD-11 definition, or were a family member or carer of one or more adults with LD. Carers could be formal, informal or from a VCSE providing service for adults with LD. Alternatively, participants were a health or social care professional who offered care or services to adults with LD and accessed a service or provided a service within HIOW. Participants were also required to provide informed consent by any means and understand and speak English.
The views of people with LD and their families and carers were collected simultaneously in combined focus groups. Participants were recruited via local VCSE groups and from community LD teams (CLDT) within HIOW Healthcare NHS Foundation Trust. Easy read versions of all key study documents were available.
A total of 12 focus groups took place, seven for people with LD, their family members and carers. All of these were conducted face-to-face at a VCSE facility and lasted between 40 to 67 minutes. Of the remaining five focus groups for health and social care professionals, three were conducted face to face at a CLDT facility, and two were conducted using Microsoft Teams. The focus groups for health and social care professionals lasted between 44 to 69 minutes. All focus groups were recorded, transcribed and pseudonymised by the study team, with participants given a unique participant identification number. Data was analysed using reflexive thematic analysis.
Results
A total of 53 participants were recruited. This included 25 individuals with LD, 4 family members, 4 voluntary sector individuals and 18 health and social care professionals. The views between each of the participant sub-groups were consistent, with no major conflicts noted and data saturation achieved.Theme 1: Informed Consent
Participants reported they would want to be given information about the study medication being investigated, whether the study may benefit them, and what their role in the study and expectations of them would be. Furthermore, 14 participants without LD said they would have concerns about how researchers ensure individuals with LD have provided informed consent. Some individuals with LD may show masking behaviours, which participants felt may further complicate the capacity assessment for researchers who lack experience in LD.
The time involved in the consenting process is also important. Nine participants expressed that offering multiple different opportunities to discuss the study with a researcher would be helpful and may be required before consent can be given. Some participants also felt they would need a longer period after receiving the study information to decide whether to participate
The need for preparatory work as part of the consenting process was evident in discussions, to ensure the individual understands why the study is being done, and why they have been invited to take part. Emphasis was also placed on the choice of terminology utilised in discussions, with plain language preferred to aid understanding. Additionally, 10 participants highlighted how crucial clear communication of study information is during the consenting process and how this should be catered to the individual’s communication needs with the use of physical tools. Patient and Public Involvement and Engagement (PPIE) is already integral in designing new clinical research studies and the importance of PPIE to create accessible study resources for people with LD was highlighted. 19 participants wanted study information available in easy-read formats and others were enthusiastic about having a variety of other formats including audio recordings, social stories, and a website. 15 participants also thought videos about the study would make information more accessible for those who cannot read.Theme 2: Perceptions of clinical research and perceived risks
The majority of participants across all focus groups had no previous involvement with any form of health research and had a limited understanding of what it entails. Despite this, when the concept of clinical research was explained during the focus groups, most participants shared a positive view on people with LD having the opportunity to take part. A few different motivations for people with LD participating in clinical research were highlighted, including the desire to help other people, particularly others with LD, and the importance of having a voice. Participants expressed that participation in clinical research could help challenge health inequalities for people with LD and offer a chance to improve their health and increase autonomy.26 participants shared concerns about possible side effects of new medications assessed in clinical trials of an investigational medicinal product (CTIMP). Some participants suggested that extra monitoring or support for side effects from research staff could mitigate this issue. Others highlighted the need for robust reporting systems for adverse events experienced by people with LD, who may require additional support to report side effects. Some of these processes already exist in clinical trials, therefore it is important to raise awareness of how these risks are monitored, recorded and managed in clinical research.
Theme 3: Involvement of the individual’s support network
22 participants highlighted the importance of involving the individual with LD's support network to aid participation, specifically care and support staff. Carer rotas and difficulties with ensuring adequate support staff accompaniment to research appointments was a significantly anticipated issue. Moreover, the need for continuity in that individual’s support staff was highlighted, as was buy-in from management responsible for care provisions. Participants also felt that study information should be provided to support staff, so that they may assist with study requirements, whether that be health monitoring at home, or medication administration. Moreover, eight participants with LD wanted their carers and support staff to discuss the research with them and 12 valued their family member’s opinions of the research study. This need for involvement of the support network also highlights the need for familiarity, given that for many individuals with LD, research will be a new and potentially stressful experience.
Participants from the professionals focus groups also discussed the importance of clinical research teams building links with primary care, CLDTs and VCSE organisations to grow research capacity and raise awareness of opportunities to take part in clinical research. As most professionals had a limited understanding of clinical research prior to the focus groups, increasing their familiarity with clinical research may allow them to better support individuals with LD to take part.Theme 4: Financial Implications
12 participants discussed financial implications that individuals with LD participating in clinical research could face. These included the costs of appropriate transport for research appointments, which participants felt should be paid for and organised by research teams. The issue of funding for additional care and support hours necessitated by participation was also raised. Moreover, if individuals with LD miss pre-paid activities or work to attend research appointments, or accept financial incentives for participation but receive benefits, this may have implications on income.Theme 5: Reasonable adjustments and person-centred approach
Participants expressed a desire for research teams to work with them to identify visit times that would fit their routine and to offer longer appointments particularly if procedures such as blood tests are required. In addition, participants expressed a wish for research visits to be held in familiar locations, or non-clinical environments which can be less emotionally challenging. Locations which could be utilised for initial discussions about research included day centres, participants’ residences, CLDT facilities and GP surgeries. Participants also suggested a guided or video tour of the research location, to aid orientation and ensure accessibility. Participants reported a desire for research staff to have knowledge and skills in working with people with LD and for there to be continuity in research staff, so that trust and rapport to be built. Suggestions included mandatory LD training for research staff, or having a LD professional embedded within the research team. Personalised care and recognition of specific needs were also emphasised.
Blood tests were a common concern amongst participants. Participants suggested using desensitisation work and distraction techniques to reduce stress from phlebotomy. Alternative methods for blood taking, such as touch activated phlebotomy, may also be a possibility for some studies.Discussion
Research to date has identified several barriers to participation, including challenges with informed consent, rigid funding formulas without allowances for addition time to enact reasonable adjustments9 and reaching target populations. As evidence shows that people with LD are inadequately included in medical research, and barriers to their involvement have been identified, there are calls for research to increase representation of this population in medical data. Furthermore, as people with LD are at greater risk at developing co-morbidities, disparities in care between those living with and without LD must be addressed.Rather than concentrating on whether people with LD can participate in clinical research studies, research teams should focus on how they enable participation. Whilst some clinical trials explicitly exclude people with LD, exclusion criteria should be clearly defined and supported by evidence to prevent discrimination. This study's findings suggest that although the inclusion of people with LD in clinical research is achievable, adjustments are required. These adjustments may impact the costs and practicalities of a clinical research study, therefore require careful thought to reduce implications on feasibility. However, without these adjustments clinical research will continue to exclude people with LD, further worsening health inequalities and underrepresentation. Adjustments that should be considered emerged as key themes in the discussions within our sample population. The views between both the LD and professionals focus groups were consistent, with no major conflicts noted and data saturation achieved.
The importance of obtaining informed consent from individuals with LD as at the forefront of discussions, with it being an ongoing process requiring flexibility and adaptation. Concerns around masking behaviors affecting capacity assessments highlighted how standard approaches may be insufficient. This could be addressed by embedding guidance around informed consent for people with LD into study protocols. Moreover, guidance around assessing capacity for professionals with limited experience working with this population should be developed.
For consent to be informed, individuals must be given study information in a way accessible to them, with the time and support they require to understand it. Findings suggested the importance of having study information available in multiple different formats. This highlights a gap between current regulatory standards and accessibility for this population, suggesting a need for a universal design in consent materials rather than just easy-read documents. Resources should be co-produced through PPIE, a process embedded in regulatory approval.
Although most participants had little prior exposure to any form of health research, they were broadly positive about being offered the opportunity to participate in clinical research. This suggests opportunities to include this population are being missed due to organisation-level failures regarding engagement, and lack of awareness of research.
In addition, many participants raised concerns about side effects of investigational medicinal products, suggesting increased vulnerability and risk sensitivity in this population. Therefore, there is a need for proactive enhanced safety monitoring whilst designing study protocols to support reporting mechanisms in this group. These mechanisms may involve carers or simplified tools. Without these frameworks, participants with LD and their support networks may struggle to report side effects, which risks underreporting bias of adverse events for CTIMPs.
Emphasis was placed on the involvement of the individual's support network being essential to facilitate participation, not optional. A lack of appropriate support could have a significant impact on recruitment and retention of participants. Our results also highlighted system-level barriers, including availability of care and support staff and lack of continuity in support to aid participation. These issues go beyond the willingness of the individual with the LD to participate, therefore need to be recognised when designing clinical research studies for people with LD.In addition, possible financial implications to those with LD were discussed, including those associated with extra support hours, transport and missed activities. Study funding must account for these true costs of participation, with transport and support hours being explicitly budgeted and incorporated as standard trial costs, to reduce the risk of indirect exclusion. Furthermore, policies regarding financial reimbursement for participants with LD should be developed to avoid any implications on benefits or care packages they receive.
Finally, the need for a person-centred approach rather than adhering to unnecessarily rigid protocols was evident from all focus groups. Emphasis was given to the need for flexibility with appointment times and durations, suggesting research activities need to align with an individual’s routine. Additionally, there is a need for adaptive clinical procedures, as demonstrated by the shared fear of blood tests present amongst participants. Where CTIMPs require non-portable equipment or facilities, study teams should consider allowing the person with LD to visit the facility in advance. This will help individuals with LD, in consultation with their carers and study team, determine feasibility of participation.
Moreover, under the Equality Act 2010, people with LD are entitled to reasonable adjustments when accessing healthcare to remove potential barriers, which is particularly pertinent when considering healthcare inequalities. Therefore, reasonable adjustments need to be embedded from a protocol level to ensure inclusive recruitment. Our findings suggest there may be a gap in the competency of the research workforce for facilitating participation of people with LD in clinical research, raising the possibility of a need for LD professionals to be working within clinical research teams.
Overall, these changes would enable us to move on from clinical research that excludes individuals with LD, to research that promotes equitable participation. This would mean people with LD are not only appropriately protected within clinical research trials, but are also meaningfully included.
Limitations
During the larger focus groups some participants would talk simultaneously despite facilitation efforts, making audio recording challenging. Larger groups also meant participants with LD had to concentrate for longer to hear all perspectives, increasing cognitive load. After a focus group with family members present, one voluntary sector participant felt some participants with LD were less vocal than usual. Whilst proxy reporting is a recognised issue in LD research, only four family members participated, limiting this impact on our findings.
Many health and social care professionals had a limited prior understanding of clinical research, therefore introductory explanations at the start of focus groups were required. Following ethics review, the research team were not permitted to recruit individuals with LD who lacked the capacity to consent to participation in this study, despite interest from several individuals. Therefore, potentially valuable perspectives from those lacking capacity may have been missed.
In addition, as qualitative data were collected through spoken focus groups, the severity of participants’ LD varied between mild-moderate as per the International Classification of Diseases classification. Therefore, this limits the representativeness of our findings for those with more severe to profound LD. Further research should explore the feasibility of implementing the aforementioned approaches across different LD severities. Finally, although the sample population reflected the local ethnic profile of Hampshire and the Isle of Wight, greater ethnic diversity should be prioritised in future research.We wish to thank all those who participated in this study for their time and invaluable contributions.
REC name
South Central - Hampshire A Research Ethics Committee
REC reference
25/SC/0366
Date of REC Opinion
8 Dec 2025
REC opinion
Further Information Favourable Opinion